Blincyto Interactions
There are 231 drugs known to interact with Blincyto (blinatumomab), along with 7 disease interactions. Of the total drug interactions, 56 are major, 174 are moderate, and 1 is minor.
- View all 231 medications that may interact with Blincyto
- View Blincyto disease interactions (7)
Most frequently checked interactions
View interaction reports for Blincyto (blinatumomab) and the medicines listed below.
- Actemra (tocilizumab)
- Adcetris (brentuximab)
- Avastin (bevacizumab)
- Baraclude (entecavir)
- Caprelsa (vandetanib)
- CellCept (mycophenolate mofetil)
- Corlanor (ivabradine)
- Cosentyx (secukinumab)
- Creon (pancrelipase)
- Cymbalta (duloxetine)
- Entyvio (vedolizumab)
- Esbriet (pirfenidone)
- Imbruvica (ibrutinib)
- Isentress (raltegravir)
- Kalydeco (ivacaftor)
- Keppra (levetiracetam)
- Kynamro (mipomersen)
- Ofev (nintedanib)
- Pomalyst (pomalidomide)
- Procysbi (cysteamine)
- Pulmozyme (dornase alfa)
- Ravicti (glycerol phenylbutyrate)
- Repatha (evolocumab)
- Revlimid (lenalidomide)
- Sabril (vigabatrin)
- Soliris (eculizumab)
- Stivarga (regorafenib)
- Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)
- Tecentriq (atezolizumab)
- Thalomid (thalidomide)
Blincyto disease interactions
There are 7 disease interactions with Blincyto (blinatumomab) which include:
- vaccination
- tumor lysis syndrome
- liver dysfunction
- neurologic disorders
- neutropenia
- pancreatitis
- renal impairment
More about Blincyto (blinatumomab)
- Blincyto consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD19 monoclonal antibodies
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.